AMEX · Financial Statements

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) Financial Statements

$1.52 AMEX: ATNM Market Cap $47.79M

Actinium Pharmaceuticals, Inc. (Delaware) most recently reported annual revenue of $0, a net loss of $34.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.

Actinium Pharmaceuticals, Inc. (Delaware): net profit was positive in 0 of 10 reported years; operating margin moved from -2182.2% to -40274.4%, a shift of -38092.3 percentage points; the most recent year shows a net loss of $34.0M.

Income Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Revenue$0$0$0$0$0$1.0M$1.0M$0$0$0
Operating Expenses$27.0M$27.0M$24.0M$22.0M$22.0M$26.0M$35.0M$52.0M$42.0M$36.0M
Operating Profit$-27.0M$-27.0M$-24.0M$-22.0M$-22.0M$-25.0M$-34.0M$-52.0M$-42.0M$-36.0M
Operating Margin0.0%0.0%0.0%0.0%0.0%-2182.2%-3311.1%-64098.8%0.0%-40274.4%
Other Income$3.0M$0$0$0$0$0$1.0M$3.0M$4.0M$2.0M
Interest$0$0$0$0$0$0$0$0$0$0
Depreciation$0$0$0$0$0$1.0M$1.0M$1.0M$1.0M$1.0M
Profit Before Tax$-24.0M$-27.0M$-24.0M$-22.0M$-22.0M$-25.0M$-33.0M$-49.0M$-38.0M$-34.0M
Tax$-20,000$0$-730,000$0$0$0$0$0$0$0
Net Profit$-24.0M$-27.0M$-24.0M$-22.0M$-22.0M$-25.0M$-33.0M$-49.0M$-38.0M$-34.0M
EPS$-15.06$-11.96$-6.69$-4.37$-1.83$-1.20$-1.37$-1.83$-1.27$-1.09
Dividend Payout0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%0.0%

Quarterly Results — Last 12 Quarters (USD millions)

8 duplicate period labels in the source data were collapsed.

MetricSep '23Dec '23Mar '24Jun '24Sep '24Dec '24Mar '25Jun '25Sep '25Dec '25Mar '26Jun '26
Revenue$0$0$0$0$0$0$0$0$0$0$0$35.0M
Operating Expenses$14.0M$10.0M$10.0M$12.0M$13.0M$8.0M$17.0M$8.0M$6.0M$6.0M$6.0M$7.0M
Operating Profit$-14.0M$-10.0M$-10.0M$-12.0M$-13.0M$-8.0M$-17.0M$-8.0M$-6.0M$-6.0M$-6.0M$28.0M
Operating Margin0.0%-12769.1%0.0%0.0%0.0%0.0%0.0%0.0%-6324.4%0.0%0.0%78.8%
Interest$0$0$0$0$0$0$0$0$0$0$0$0
Profit Before Tax$-13.0M$-9.0M$-9.0M$-11.0M$-12.0M$-7.0M$-16.0M$-7.0M$-5.0M$-6.0M$-6.0M$28.0M
Tax$0$0$0$0$0$0$0$0$0$0$0$0
Net Profit$-13.0M$-9.0M$-9.0M$-11.0M$-12.0M$-7.0M$-16.0M$-7.0M$-5.0M$-6.0M$-6.0M$28.0M
EPS$-0.49$-0.34$-0.31$-0.38$-0.37$-0.21$-0.51$-0.22$-0.16$-0.19$-0.18$0.89

Over the 10 years reported for Actinium Pharmaceuticals, Inc. (Delaware), cash stood at $48.0M in the latest year, shareholders' equity was $0, current assets covered current liabilities 6.13 times.

Balance Sheet — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Total Assets$23.0M$18.0M$15.0M$12.0M$66.0M$80.0M$114.0M$81.0M$77.0M$52.0M
Current Assets$22.0M$18.0M$14.0M$10.0M$65.0M$80.0M$111.0M$78.0M$75.0M$49.0M
Cash$21.0M$17.0M$14.0M$9.0M$64.0M$78.0M$109.0M$77.0M$73.0M$48.0M
Inventory$0$0$0$0$0$0$0$0$0$0
Receivables$0$0$0$0$0$0$0$0$0$0
Fixed Assets$0$0$0$1.0M$1.0M$1.0M$3.0M$3.0M$2.0M$2.0M
Capital Work in Progress$0$0$0$0$0$0$0$0$0$0
Investments$0$0$0$0$0$0$0$0$0$0
Other Assets$0$0$0$0$0$0$0$0$0$0
Total Liabilities$5.0M$5.0M$6.0M$6.0M$5.0M$7.0M$48.0M$45.0M$44.0M$44.0M
Current Liabilities$5.0M$5.0M$6.0M$5.0M$5.0M$7.0M$11.0M$8.0M$8.0M$8.0M
Borrowings$0$0$0$1.0M$1.0M$0$3.0M$2.0M$2.0M$2.0M
Other Liabilities$5.0M$5.0M$6.0M$5.0M$4.0M$7.0M$45.0M$43.0M$43.0M$42.0M
Equity$0$0$0$0$0$0$0$0$0$0
Reserves$18.0M$14.0M$9.0M$6.0M$61.0M$74.0M$66.0M$36.0M$33.0M$8.0M

For Actinium Pharmaceuticals, Inc. (Delaware), operating cash flow was positive in 1 of 10 reported years; free cash flow in the latest year was negative at $25.0M; free cash flow was positive in 1 of 10 years.

Cash Flow Statement — 10 Years (USD millions)

Metric2016201720182019202020212022202320242025
Operating Cash Flow$-21.0M$-22.0M$-21.0M$-21.0M$-22.0M$-21.0M$9.0M$-47.0M$-33.0M$-25.0M
Investing Cash Flow$0$-1.0M$0$0$-1.0M$0$-1.0M$0$0$0
Financing Cash Flow$0$0$0$2.0M$0$0$0$0$0$0
Net Cash Flow$-5.0M$-3.0M$-4.0M$-4.0M$54.0M$14.0M$31.0M$-33.0M$-4.0M$-25.0M
Free Cash Flow$-21.0M$-22.0M$-21.0M$-22.0M$-22.0M$-21.0M$8.0M$-47.0M$-33.0M$-25.0M

Valuation & Return Ratios

MetricValue
PEG Ratio0.01
EV / EBITDA0.13
FCF Yield-63.33%
Quick Ratio4.08
Interest Coverage—
Return 1Y-38.58%
Return 3Y-86.91%
Return 5Y-87.25%

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) financials — frequently asked questions

What is Actinium Pharmaceuticals, Inc. (Delaware)'s annual revenue?

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) reported annual revenue of $0 in its most recent fiscal year.

What is Actinium Pharmaceuticals, Inc. (Delaware)'s net profit?

Actinium Pharmaceuticals, Inc. (Delaware) (ATNM) reported a net loss of $34.0M in its most recent fiscal year.

What is ATNM EV/EBITDA?

Actinium Pharmaceuticals, Inc. (Delaware)'s enterprise value to EBITDA (EV/EBITDA) ratio is 0.13.

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)Eli Lilly (LLY)JPMorgan (JPM)

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksAll stock screens
ATNM Overview ATNM Dividend Run Stock Screener

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.